Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis
ConclusionsICIs appear to be effective in patients aged ≥ 75 years. However, the survival benefit is mainly observed in first-line treatment and remains unclear in the second-line setting.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Gastric (Stomach) Cancer | Gastroenterology | Geriatrics | Head and Neck Cancer | HNSCC | Kidney Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Skin Cancer | Squamous Cell Carcinoma | Statistics | Study | Yervoy